Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
11/03/26	0.0540 $	-1.82%	10,274,280
10/03/26	0.0550 $	+1.85%	12,578,430
09/03/26	0.0540 $	-5.26%	14,674,660
06/03/26	0.0570 $	-1.72%	8,634,295
05/03/26	0.0580 $	+5.45%	15,373,250

Delayed Quote Australian S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0550AUD

Average target price

0.4967AUD

Spread / Average Target

+803.04%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Australian S.E. Other stock markets 04:10:29 11/03/26 pm AEDT			5-day change	1st Jan Change
0.0540 ^AUD	-1.82%		-1.82%	-60.00%

10/03	Botanix Pharmaceuticals' Axillary Hyperhidrosis Product Outsells Competing Product, Says Euroz Hartleys	MT
03/03	Botanix Pharmaceuticals Limited, Q2 2026 Earnings Call, Mar 03, 2026

Capitalization	122M 87.13M 74.82M 67.63M 64.75M 118M 8B 797M 319M 3.84B 327M 320M 13.74B	P/E ratio 2026 *	-2.75x	P/E ratio 2027 *	-4.78x
Enterprise value	116M 82.84M 71.14M 64.3M 61.57M 112M 7.61B 757M 303M 3.65B 311M 304M 13.06B	EV / Sales 2026 *	2.88x	EV / Sales 2027 *	1.54x
Free-Float	87.72%	Yield 2026 *	-	Yield 2027 *	-

10/03	Botanix Pharmaceuticals' Axillary Hyperhidrosis Product Outsells Competing Product, Says Euroz Hartleys	MT
03/03	Botanix Pharmaceuticals Limited, Q2 2026 Earnings Call, Mar 03, 2026
27/02	Botanix Pharmaceuticals posts hy loss attributable a$33.2 million	RE
27/02	Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
17/02	Botanix Pharmaceuticals to Raise About AU$40 Million via Share Placement; Shares Hit Three-Year Low	MT
17/02	Botanix Pharmaceuticals receives firm commitments for A$40 million two-tranche placement	RE
13/02	Botanix Pharmaceuticals requests trading halt	RE
27/01	Botanix Pharmaceuticals Limited - Special Call
30/12	Botanix Pharmaceuticals Buys Back Nearly 7 Million Ordinary Shares	MT
20/11	Botanix Pharmaceuticals Shareholders Reject Remuneration Report	MT
21/10/25	Botanix Pharmaceuticals to Not Rely Upon ASX Partial Waiver After Verifying Sufficient Securities Under its Placement Capacity	MT
20/10/25	Botanix Pharmaceuticals Back On Track With Reduced Cash Burn, Euroz Hartleys Says	MT
20/10/25	Botanix Pharmaceuticals says Sofdra net revenue amounted to A$7.1 million in Q1 FY26	RE

24/09/25	Botanix Pharmaceuticals' Sofdra Topical Gel Dermatologists' Preferred Option for Hyperhidrosis Treatment in Survey, Euroz Hartleys Says	MT
18/09/25	Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says	MT
13/05/25	Botanix Pharmaceuticals Not Expected to be Impacted by Trump's Executive Orders, Euroz Hartleys Says	MT
10/02/25	Sales Traction from Botanix Pharmaceuticals' Prescription Gel Launch May Drive Stock Re-rating, Euroz Hartleys Says	MT
02/07/24	Euroz Hartleys Upgrades Botanix Pharmaceuticals' to Buy From Speculative Buy, Adjusts Price Target to AU$0.47 From AU$0.33	MT

Botanix Pharmaceuticals Limited Stock

Equities

BOT

AU000000BOT2

Pharmaceuticals

Valuation: Botanix Pharmaceuticals Limited

Chart: Botanix Pharmaceuticals Limited

Latest news: Botanix Pharmaceuticals Limited

Last Transcript: Botanix Pharmaceuticals Limited

Analysts' recommendations: Botanix Pharmaceuticals Limited

Press Releases: Botanix Pharmaceuticals Limited

Quotes and Performance

Course Extremes

Managers and Directors: Botanix Pharmaceuticals Limited

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

22/01	Botanix Pharmaceuticals : Quarterly Update Webinar 27 January \| Registration Open	PU
10/11	Botanix Pharmaceuticals : Sofdra posters presented at dermatology conferences	PU
20/10/25	Botanix Pharmaceuticals : Releases Quarterly Reports	PU
16/10/25	Botanix Pharmaceuticals : Quarterly Update Webinar October 20 \| Registration Open	PU
17/03/25	Botanix Pharmaceuticals : Stockhead \| Interview with Howie McKibbon	PU

1 day	-1.82%
1 week	-1.82%
Current month	-3.57%
1 month	-50.91%
3 months	-53.04%
6 months	-50.91%
Current year	-60.00%

1 week	0.05	0.06
1 month	0.05	0.12
Current year	0.05	0.15
1 year	0.05	0.48
3 years	0.05	0.54
5 years	0.05	0.54
10 years	0.02	0.54

Manager	Title	Age	Since
Howie McKibbon CEO	Chief Executive Officer	-	24/08/2023
Graeme Morissey DFI	Director of Finance/CFO	-	26/03/2024
Vincent Ippolito PSD	President	67	20/05/2019

Director	Title	Age	Since
Henry Bosch BRD	Director/Board Member	-	01/07/2016
Stewart Washer CHM	Chairman	56	21/02/2019
Vincent Ippolito CHM	Chairman	67	18/07/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BOTANIX PHARMACEUTICALS LIMITED	-1.82%	-1.82%	-86.83%	-46.00%	87.13M
MERCK KGAA	+0.05%	-10.28%	-17.73%	-35.00%	56.2B
HALOZYME THERAPEUTICS, INC.	-0.48%	-2.29%	+10.37%	+62.89%	8B
KYOWA KIRIN CO., LTD.	+0.68%	+2.96%	+3.31%	-19.18%	7.58B
SK BIOPHARMACEUTICALS CO., LTD.	+1.83%	-9.35%	-6.90%	+60.10%	5.34B
YUHAN CORPORATION	+2.18%	-7.51%	-18.26%	+100.44%	4.99B
SUPERNUS PHARMACEUTICALS, INC.	-0.92%	-1.63%	+63.43%	+53.47%	3.09B
BETTA PHARMACEUTICALS CO., LTD.	+2.39%	+4.81%	-13.29%	-17.50%	2.72B
MEZZION PHARMA CO.,LTD.	+1.50%	-2.79%	+349.91%	+611.37%	2.67B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.30%	+1.51%	+39.74%	+39.89%	2.51B
Average	+0.66%	-0.19%	+32.37%	+81.05%	9.32B
Weighted average by Cap.	+0.28%	-5.77%	+1.83%	+11.38%

	2026 *	2027 *
Net sales	40.25M 28.75M 24.68M 22.31M 21.36M 39.02M 2.64B 263M 105M 1.27B 108M 106M 4.53B	87.4M 62.42M 53.6M 48.45M 46.39M 84.73M 5.73B 571M 229M 2.75B 234M 229M 9.84B
Net income	-59.5M -42.49M -36.49M -32.98M -31.58M -57.68M -3.9B -388M -156M -1.87B -159M -156M -6.7B	-26.63M -19.02M -16.33M -14.76M -14.14M -25.82M -1.75B -174M -69.63M -838M -71.39M -69.87M -3B
Net Debt	-6M -4.29M -3.68M -3.33M -3.18M -5.82M -394M -39.17M -15.69M -189M -16.08M -15.74M -676M	12.3M 8.78M 7.54M 6.82M 6.53M 11.92M 807M 80.31M 32.16M 387M 32.97M 32.27M 1.38B